Univariate | Multivariate | ||||||
Parameter | Group | HR | 95% CI | P | HR | 95% CI | P |
Ki-67 | Q1: <2% | 1 | 0.001 | 1 | 0.014 | ||
Q2: 2%–5% | 1.340 | 0.960–1.871 | 1.363 | 0.946–1.965 | |||
Q3: 5%–10% | 1.519 | 1.051–2.194 | 1.203 | 0.798–1.814 | |||
Q4: >10% | 2.143 | 1.488–3.087 | 1.930 | 1.285–2.899 | |||
Performance status | WHO 0 | 1 | <0.001 | 1 | 0.010 | ||
WHO 1 | 1.781 | 1.432–2.214 | 1.551 | 1.109–2.169 | |||
WHO 2–3 | 2.817 | 1.941–4.089 | 2.305 | 1.432–3.713 | |||
Prior treatment | Ablation | 1.458 | 1.103–1.928 | 0.008 | 1.519 | 1.041–2.215 | 0.030 |
Chemotherapy | 1.792 | 1.434–2.239 | <0.001 | 1.979 | 1.412–2.773 | <0.001 | |
CgA (μg/L) | Q1: <112 | 1 | <0.001 | 1 | <0.001 | ||
Q2: 112–336 | 1.531 | 1.100–2.131 | 1.690 | 1.095–2.608 | |||
Q3: 336–1,168 | 1.887 | 1.354–2.631 | 1.816 | 1.718–2.799 | |||
Q4: >1,168 | 3.357 | 2.434–4.631 | 2.671 | 1.717–4.155 |
HR > 1 indicates greater risk for death of any cause and HR < 1 lower risk.